Released Aug 3, 2022, after the close
10-Q filed Aug 3, 2022, 34 days after period end · 0000950170-22-014236
Q2 2022 · 10-Q
Revenue$18.55M$18.55M +38.3% vs Q2 2021+0.7% vs Q1 2022
Net Income-$76.11M-$76.11M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.79-$0.79 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$83,109,000N/M
Operating Cash Flowderived-$53,159,000N/M
Free Cash Flowderived-$63,288,000N/M
Margins · derived
Operating margin-448.1%−99.3 pt vs Q2 2021
Net margin-410.3%+0.8 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $18.55M | $13.41M | $5.47M | $2.82M |
| Net Income | -$76.11M | -$55.13M | -$28.07M | -$23.48M |
| EPS Diluted | -$0.79 | -$0.58 | -$0.35 | -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR